HAVCR2 and psoriasis: In psoriasis patients, Th1/Th17 effectors fail to appropriately up-induce TIM3, and TIM3–negative cells produce more IFN-γ/IL-17, consistent with loss of a local “brake” on type-1/17 immunity [29].